<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976741</url>
  </required_header>
  <id_info>
    <org_study_id>16443</org_study_id>
    <secondary_id>2013-002155-15</secondary_id>
    <nct_id>NCT01976741</nct_id>
  </id_info>
  <brief_title>Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</brief_title>
  <official_title>An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  This is the first study where BAY1163877 is given to humans. Impact of the study is to
           evaluate if patients with advanced solid cancers show advanced clinical benefit under
           the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study
           drug treatment in a dose-escalation scheme (no placebo group) to determine the safety,
           tolerability and maximum tolerated dose (MTD) of BAY1163877. The relative
           bioavailability of liquid service formulation and tablets will be determined.

        -  After the MTD is defined patients with solid tumors (all comers), lung cancer (lung
           adenocarcinoma &amp; squamous non-small cell lung cancer), head and neck cancer or bladder
           cancer will be enrolled according to their FGFR expression profile (biomarker
           stratification).

        -  The study will also assess the pharmacokinetics, biomarker status, pharmacodynamic
           parameters and tumor response of BAY1163877.

        -  BAY1163877 will be given twice daily as oral application. Treatment will be stopped if
           the tumor continues to grow, if side effects, which the patient cannot tolerate, occur
           or if the patient decides to exit treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2013</start_date>
  <completion_date type="Anticipated">July 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD), defined as maximum dose at which the incidence of Drug Limiting Toxicities (DLTs) during cycle 1 is below 20%</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax(maximum drug concentration in plasma after first dose administration)</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12) (AUC from time zero to 12 hours p.a. after first-dose administration</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast) (AUC from time zero to the last data point &gt; LLOQ)</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the plasma concentration vs time curve from zero to infinity after single (first) dose)</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax/D (maximum drug concentration in plasma after single dose administration divided by dose)</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)/D(AUC from time zero to 12 hours after single dose administration divided by dose)</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)/D (AUC from time zero to the last data point &gt;&gt;LLOQ(lower limit of quantification) after single dose administration divided by dose</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC/D (AUC divided by dose)</measure>
    <time_frame>Cycle 1 day -3 and cycle 1,day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md (Cmax after multiple-dose administration)</measure>
    <time_frame>Cycle1, day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax/Dmd (Maximum drug concentration in plasma after multiple dose administration divided by dose)</measure>
    <time_frame>Cycle1, day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md (AUC(0-12) after multiple-dose administration)</measure>
    <time_frame>Cycle1, day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)/Dmd (AUC from time zero to 12 hours after multiple dose administration divided by dose</measure>
    <time_frame>Cycle1, day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)md (AUC from time zero to the last data point&gt;LLOQ after multiple dose administration)</measure>
    <time_frame>Cycle1, day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)/Dmd (AUC from time zero to the last data point&gt;LLOQ after multiple dose administration divided by dose)</measure>
    <time_frame>Cycle1, day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(0-12) amount of drug excreted via urine during the collection interval 0 - 12 hours post administration</measure>
    <time_frame>Cycle1, day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(0-24) amount of drug excreted via urine during the collection interval 0 - 24 hours post administration</measure>
    <time_frame>Cycle1, day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(12-24) amount of drug excreted via urine during the collection interval 12 - 24 hours post administration</measure>
    <time_frame>Cycle1, day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response evaluation based on RECIST 1.1</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of biomarker status</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacodynamic Parameters (PD)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of relative bioabailability of the tablet formulation in comparison to the solution formulation of BAY1163877</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Rogaratinib (BAY1163877)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rogaratinib (BAY1163877)</intervention_name>
    <description>Oral administration twice daily. Starting dose is 100 mg per patient in the first cohort and will be escalated in other cohorts depending on any dose-limiting toxicities.</description>
    <arm_group_label>Rogaratinib (BAY1163877)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For dose escalation: Subjects with any type of solid tumor (all comer) will be
             eligible for dose escalation and dose expansion at MTD in Part 1; Subjects enrolled
             for dose expansion (MTD expansion cohort &quot;all comer&quot;) will be stratified according to
             high fibroblast growth factor receptor (FGFR) expression levels / FGFR mutation using
             archival or fresh tumor biopsy material

          -  For expansion cohorts: Subjects will be eligible for Part 2 only if they have
             histological or cytological confirmed squamous non-small cell lung cancer (sqNSCLC),
             lung adenocarcinoma, head and neck cancer or bladder cancer (BC). All subjects in Part
             2 will be stratified according to high FGFR expression levels FGFR mutation using
             archival or fresh tumor biopsy specimen. BC subjects with low overall FGFR expression
             levels can be included if activating FGFR3(FGFR tyrosine kinases3) mutations are
             confirmed

          -  Subjects must have measurable disease (Response evaluation criteria in solid tumors
             (RECIST 1.1))

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2

          -  Bone marrow, liver and renal functions as assessed by adequate laboratory methods to
             be conducted within 7 days prior to starting study Treatment

          -  Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2 according to the modified diet in
             renal disease (MDRD) abbreviated formula

        Exclusion Criteria:

          -  Previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase
             inhibitors or FGFR-specific antibodies)

          -  Concomitant therapies that cannot be discontinued or switched to a different
             medication prior to study entry that are known to increase serum phosphate levels are
             not permitted within 4 weeks prior to start of study treatment)

          -  Anticancer chemotherapy or immunotherapy during the study or within 5-halflives prior
             to start of study treatment. Mitomycin C, nitrosoureas or monoclonal antibodies with
             anticancer activity (e.g. bevacizumab or cetuximab etc.) should not be given within 6
             weeks before starting to receive study treatment or within 6 weeks of pre-treatment
             biopsy for biomarker (p-ERK1/2) studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Weiden</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <state>Graubünden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>refractory, locally advanced or metastatic solid tumor</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>squamous non-small cell lung cancer</keyword>
  <keyword>pan-FGFR inhibitor</keyword>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>head and neck cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

